CVS Health (NYSE:CVS) Given New $110.00 Price Target at Cantor Fitzgerald

CVS Health (NYSE:CVS) had its target price raised by research analysts at Cantor Fitzgerald from $100.00 to $110.00 in a report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the pharmacy operator’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 7.71% from the stock’s current price.

CVS has been the subject of several other research reports. Wells Fargo & Company lifted their price objective on shares of CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. TD Cowen raised their price target on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Bank of America upped their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Argus raised their target price on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. Finally, Morgan Stanley upped their price target on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Twenty-one investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and an average target price of $102.60.

CVS Health Stock Performance

CVS stock opened at $102.13 on Tuesday. The firm has a market cap of $130.31 billion, a PE ratio of 44.99, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The stock has a 50-day moving average price of $94.56 and a 200-day moving average price of $83.31. CVS Health has a 1-year low of $58.50 and a 1-year high of $106.15.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter last year, the firm posted $2.25 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities research analysts expect that CVS Health will post 7.44 earnings per share for the current year.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This trade represents a 24.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Company insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CVS. Boltwood Capital Management raised its stake in shares of CVS Health by 7.1% during the 2nd quarter. Boltwood Capital Management now owns 9,407 shares of the pharmacy operator’s stock worth $973,000 after purchasing an additional 622 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in CVS Health by 8.7% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 4,135 shares of the pharmacy operator’s stock worth $428,000 after acquiring an additional 330 shares during the period. First County Bank CT bought a new position in shares of CVS Health during the 2nd quarter valued at approximately $252,000. Redwood Investment Management LLC raised its holdings in shares of CVS Health by 6.5% in the 1st quarter. Redwood Investment Management LLC now owns 10,212 shares of the pharmacy operator’s stock worth $733,000 after purchasing an additional 623 shares during the period. Finally, Sapient Capital LLC bought a new position in CVS Health during the first quarter valued at $204,000. Institutional investors own 80.66% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is being promoted as a momentum stock and a potential pick for investors looking for names with strong technical or sentiment-driven upside. Are You Looking for a Top Momentum Pick? Why CVS Health (CVS) is a Great Choice
• Positive Sentiment: Analyst-style commentary argued that CVS is a healthcare outlier with a credible turnaround story, citing a Q1 beat-and-raise, expected margin expansion in 2026, and improving business execution. CVS Health: The Surprising Healthcare Outlier
• Positive Sentiment: Jim Cramer’s favorable view on CVS has also been cited as a catalyst, reinforcing investor confidence in the stock’s outlook. CVS Health Corporation (CVS) Shares Up Significantly After Jim Cramer Said He Was Looking For A Good Year
• Neutral Sentiment: CVS announced it will hold its second-quarter 2026 earnings call on August 5, which keeps investors focused on upcoming results but does not change fundamentals by itself. CVS Health to hold second quarter 2026 earnings conference call
• Neutral Sentiment: The CVS Health Foundation’s $1 million donation to Hartford nonprofits supports community health efforts and is positive for reputation, but it is unlikely to move the stock materially on its own. CVS Health Foundation Invests $1 Million in Hartford Nonprofits Tackling Community Health Needs
• Negative Sentiment: CVS-branded medicated wipes were recalled due to a child poisoning risk, which could create a small reputational headwind for the company and its retail business. Over 75,000 CVS medicated wipes recalled nationwide due to severe child poisoning risk
• Negative Sentiment: Another recall-related report flagged CVS medicated wipes over child safety concerns, adding to short-term product-safety pressure. CVS Health medicated wipes recalled over child safety concerns

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.